If one looks at the business plan as a start up biotech- it would be quite impressive. If one looks at this as a 25 year company managed by a team that really wasn't sure of its pivotal Ph3 and is essentially starting over- this is quite depressing. I think the answer is somewhere in between Hopefully, these small unblinded trials can yield some results quickly, while the rest of the business model accelerates.
They need to get on with the RS and start building back the share price. It is just weight on shareprice. Well what they should really do if the bod actually protected shareholders is; spin-out Avid, sell ip with tax credits o a real company and resign.
News 
Market Data 
Discover 
AI
